TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24269077
Drug: Intensive, individual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive, individual dietary counseling (1 hour per week) and daily oral nutritional supplement (2531 kJ, 33.8 g protein, 2.2 g EPA)
Study: 17276552
Drug: Two-dose hepatitis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-dose hepatitis B immunisation (20 microg HBsAg doses 6 months apart)
Study: 17276552
Drug: Three-dose hepatitis
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-dose hepatitis B immunisation (10 microg HBsAg doses at 0, 1, 6 months)
Study: 12677149
Drug: Lansoprazole (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole (30 mg/d) for 12 weeks postoperatively
Study: 1615132
Drug: Intravenous fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous fentanyl (0, 25, 50, 100 micrograms/70 kg)
Study: 6496915
Drug: Bupivacaine during
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine during intravenous regional analgesia
Study: 3514155
Drug: Clobetasol propionate
Normalized name: Clobetasol Propionate
DrugBank: Clobetasol propionate (DB01013)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Clobetasol propionate 0.05 percent ointment
Study: 3514155
Drug: Betamethasone dipropionate
Normalized name: Betamethasone Dipropionate
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betamethasone dipropionate 0.05 percent ointment
Study: 24084921
Drug: CEE plus
Normalized name: Ecee Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE plus MPA (0.625 mg/d CEE + 2.5 mg/d MPA)
Study: 24084921
Drug: CEE alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE alone (0.625 mg/d CEE)
Study: 16618262
Drug: Acetaminophen 250
Normalized name: acetaminophen 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 250 mg, Aspirin 250 mg, Caffeine 65 mg per tablet (AAC)
Study: 16618262
Drug: Ibuprofen 200
Normalized name: ibuprofen 200 MG
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen 200 mg per tablet (IB)
Study: 7582397
Drug: Oral estradiol
Normalized name: estradiol Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral estradiol treatment
Study: 9428032
Drug: L‐mode (non-linear
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐mode (non-linear amplification mode)
Study: 1403041
Drug: Etoposide with
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Etoposide with high-dose cyclosporine (CsA)
Study: 29124831
Drug: Oral methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral methotrexate
Study: 31730666
Drug: Topical lactic
Normalized name: lactic acid Topical Lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical lactic acid gel
Study: 31730666
Drug: Oral metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral metronidazole antibiotic
Study: 27317968
Drug: Oral ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ketamine (150mg daily)
Study: 27317968
Drug: Diclofenac (150mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac (150mg daily)
Study: 20438378
Drug: Initial HIV
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial HIV therapy strategies (specific strategies not detailed in the abstract)
Study: 12807526
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg eletriptan (E40)
Study: 12807526
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg eletriptan (E80)
Study: 10806014
Drug: Short-term treatment
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term treatment effects on ischaemia
Study: 1672389
Drug: Intramuscular vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular vaccination of children aged between 0 and 4 years
Study: 1672389
Drug: Intramuscular vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular vaccination of children between 1 and 9 months old
Study: 1672389
Drug: Intradermal vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal vaccination regimens
Study: 6141797
Drug: Test preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test preparation (Normoc)
Study: 6141797
Drug: Standard preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard preparation (commercially available)
Study: 28826313
Drug: Omega-3 supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 supplementation (1,200 mg daily for 8 weeks)
Study: 26208048
Drug: Citalopram 20
Normalized name: citalopram 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram 20 mg per day for the first week, followed by 40 mg per day from weeks 2 through 12
Study: 23841970
Drug: Horseback riding
Normalized name: zinc gluconate
DrugBank: Zinc gluconate (DB11248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Horseback riding therapy (HBRT) plus conventional physiotherapy for 16 weeks
Study: 23841970
Drug: Horseback riding
Normalized name: zinc gluconate
DrugBank: Zinc gluconate (DB11248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Horseback riding therapy (HBRT) plus conventional physiotherapy
Study: 7525661
Drug: Intravenous FK506
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous FK506 (20 micrograms/kg x 4 hours)
Study: 7525661
Drug: Oral FK506
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral FK506 (80 micrograms/kg)
Study: 3310632
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g four times daily (group A, n = 131)
Study: 3310632
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g twice daily (group B, n = 128)
Study: 3310632
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g four times daily (group A)
Study: 3310632
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g twice daily (group B)
Study: 27187435
Drug: Brazilian green
Normalized name: BRAZILIAN PEPPER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brazilian green propolis (900 mg/day)
Study: 20609003
Drug: VAAM ingestion
Approvals — FDA: no, EMA: no, PMDA: no
Description: VAAM ingestion (3000 mg/day)
Study: 18726947
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg of oral desmopressin
Study: 8739022
Drug: CGP 36,742
Approvals — FDA: no, EMA: no, PMDA: no
Description: CGP 36,742 (600 mg single oral dose)
Study: 2127791
Drug: Recombinant interferon
Normalized name: Recombinant Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant interferon alfa‐2a (6 million units thrice weekly for 1 month, followed by 3 million units for 3 months, and 1 million units maintenance therapy for 8 months)
Study: 2127791
Drug: Retrospective analysis
Normalized name: Chemicals and reagents for analysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retrospective analysis of patients' sera for antibody to hepatitis C virus
Study: 31142242
Drug: Hydrocortisone monotherapy
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone monotherapy
Study: 25533997
Drug: Fluoxetine (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (single dose)
Study: 21479856
Drug: CEUS (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEUS (all doses combined)
Study: 18467147
Drug: Skin infiltration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Skin infiltration with 20 ml of ropivacaine 0.75% (Gr R)
Study: 18467147
Drug: Skin infiltration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Skin infiltration with 20 ml of 0.9% saline solution (Gr P)
Study: 16204359
Drug: Theophylline (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (1 mg/kg IV for three days)
Study: 7824566
Drug: 0.30% menthol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.30% menthol solution
Study: 7824566
Drug: 0.03% menthol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.03% menthol solution
Study: 26201312
Drug: VPZ 5
Normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: VPZ 5 mg
Study: 26201312
Drug: VPZ 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: VPZ 10 mg
Study: 26201312
Drug: VPZ 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: VPZ 20 mg
Study: 26201312
Drug: VPZ 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: VPZ 40 mg
Study: 24213913
Drug: Guideline-adherent therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guideline-adherent therapy
Study: 24213913
Drug: Non-guideline-adherent therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-guideline-adherent therapy
Study: 24213913
Drug: Guideline-recommended combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guideline-recommended combination of amoxicillin-gentamicin
Study: 24213913
Drug: Guideline-adherent therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guideline-adherent therapy for patients with a catheter
Study: 19043984
Drug: Allergen immunotherapy
Normalized name: Allergen immunotherapy extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allergen immunotherapy with allergens absorbed on calcium phosphate
Study: 19043984
Drug: Allergen immunotherapy
Normalized name: Allergen immunotherapy extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allergen immunotherapy with allergens absorbed on aluminium hydroxide
Study: 8694325
Drug: Epidural sufentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural sufentanil 1 microgram/mL at thoracic level (Ts)
Study: 8694325
Drug: Epidural sufentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural sufentanil 1 microgram/mL at lumbar level (Ls)
Study: 8694325
Drug: Epidural sufentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural sufentanil 1 microgram/mL combined with bupivacaine 1 mg/mL at thoracic level (Tsb)
Study: 8694325
Drug: Epidural infusion
Normalized name: epidural administration set EPIDURAL INFUSION SETS-PARAPHERNALIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural infusion (all groups)
Study: 28482858
Drug: Dose reduction
Normalized name: Rebetron Combination Package for Rebetol Dose Reduction, Intron A 6,000,000 UNT/ML Multi-Dose Vial / 42 Rebetol Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose reduction group (33% and 50% dose reduction of biologics)
Study: 28482858
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (no dose reduction)
Study: 28482858
Drug: Dose reduction
Normalized name: Rebetron Combination Package for Rebetol Dose Reduction, Intron A 6,000,000 UNT/ML Multi-Dose Vial / 42 Rebetol Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose reduction group
Study: 26185017
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of ACE-inhibitors
Study: 26185017
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of diuretics, insulin, and digitalis
Study: 26185017
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of diuretic and ACE-inhibitor
Study: 23480640
Drug: Twice-daily darunavir/ritonavir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-daily darunavir/ritonavir (DRV/r) 600/100 mg
Study: 20854382
Drug: Lisinopril 20,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril 20, 40 and 60 mg daily
Study: 16982943
Drug: Bosentan (62.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bosentan (62.5 mg for 1 day and 125 mg for the following 2 days)
Study: 15339556
Drug: Cinobufacini injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinobufacini injection
Study: 10726719
Drug: Per 2/Ind
Approvals — FDA: no, EMA: no, PMDA: no
Description: Per 2/Ind 0.625 mg
Study: 10726719
Drug: Per 4/Ind
Approvals — FDA: no, EMA: no, PMDA: no
Description: Per 4/Ind 1.25 mg
Study: 10726719
Drug: Per 8/Ind
Approvals — FDA: no, EMA: no, PMDA: no
Description: Per 8/Ind 2.5 mg
Study: 10726719
Drug: Per 0/Ind
Approvals — FDA: no, EMA: no, PMDA: no
Description: Per 0/Ind 1.25 mg
Study: 10726719
Drug: Per 2/Ind
Approvals — FDA: no, EMA: no, PMDA: no
Description: Per 2/Ind 1.25 mg
Study: 10726719
Drug: Other doses
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other doses (0-4.6%)
Study: 1485136
Drug: Chondroitin sulfate
Normalized name: Chondroitin Sulfate
DrugBank: Chondroitin sulfate (DB09301)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chondroitin sulfate (4 capsules/day)
Study: 6585371
Drug: Tetracycline therapy
Normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tetracycline therapy for 2 weeks
Study: 6585371
Drug: Metronidazole therapy
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metronidazole therapy for 1 week
Study: 6585371
Drug: Combined systemic
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined systemic antimicrobial therapy and mechanical plaque control
Study: 31237183
Drug: Tryptophan (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tryptophan (1000 mg/day)
Study: 31237183
Drug: Placebo (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1000 mg/day)
Study: 22716975
Drug: Zidovudine for
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zidovudine for 6 weeks plus three doses of nevirapine during the first 8 days of life (two-drug group)
Study: 22716975
Drug: Zidovudine for
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zidovudine for 6 weeks plus nelfinavir and lamivudine for 2 weeks (three-drug group)
Study: 8676931
Drug: Three-drug group
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-drug group
Study: 17683996
Drug: Intravenous clodronate
Normalized name: Clodronic acid
DrugBank: Clodronic acid (DB00720)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous clodronate (900 mg, n = 33)
Study: 11880863
Drug: Melatonin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (3 mg p.o., fast release form)
Study: 7000598
Drug: Chlorpropamide treatment
Normalized name: Chlorpropamide
DrugBank: Chlorpropamide (DB00672)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorpropamide treatment in insulin dependent diabetics
Study: 7000598
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no chlorpropamide treatment)
Study: 7000598
Drug: Non-insulin dependent
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Non-insulin dependent diabetics
Study: 7000598
Drug: Non-insulin dependent
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Non-insulin dependent diabetics with family history
Study: 23599979
Drug: Target controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Target controlled infusion of remifentanil at 1 f.Lg/L (group A)
Study: 23599979
Drug: Target controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Target controlled infusion of remifentanil at 2 f.Lg/L (group B)
Study: 23599979
Drug: Target controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Target controlled infusion of remifentanil at 3 f.Lg/L (group C)
Study: 23599979
Drug: Target controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Target controlled infusion of remifentanil at 4 f.Lg/L (group D)
Study: 21398087
Drug: Subcutaneous ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous ketamine infusion (0.1, 0.15, or 0.2 mg/kg/h)
Study: 21398087
Drug: Oral ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ketamine (300 mg/day, interquartile range 240-382.5)
Study: 18608549
Drug: 50 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 g/day soy protein containing 164 mg isoflavones
Study: 16395099
Drug: C-reactive protein
Normalized name: C-reactive protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: C-reactive protein (CRP) levels > or = 40 mg/dL
Study: 16395099
Drug: C-reactive protein
Normalized name: C-reactive protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: C-reactive protein (CRP) levels > or = 120 mg/dL
Study: 16395099
Drug: C-LRTI with
Approvals — FDA: no, EMA: no, PMDA: no
Description: C-LRTI with CRP levels > or = 40 mg/dL
Study: 9226527
Drug: Nizatidine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nizatidine (10 mg/kg/day in two doses for 8 weeks)
Study: 8434246
Drug: Rifampicin 600
Normalized name: Rifampicin 600 mg powder for solution for infusion vial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampicin 600 mg daily
Study: 8434246
Drug: Hydroxychloroquine (HCQ)
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroxychloroquine (HCQ) 400 mg daily
Study: 2885356
Drug: Diphenhydramine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diphenhydramine (50 mg three times a day)
Study: 2885356
Drug: Loratadine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loratadine (10 mg and 40 mg)
Study: 22435439
Drug: Zinc sulfate
Normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc sulfate 220 mg twice daily for 90 days
Study: 11112236
Drug: Anticoagulant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulant therapy (unfractionated heparin or low‐molecular‐weight heparin (reviparin) and a coumarin derivative)
Study: 1350237
Drug: Pramipexole 0.1
Normalized name: pramipexole 0.125 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pramipexole 0.1 mg
Study: 1350237
Drug: Pramipexole 0.2
Normalized name: pramipexole 0.25 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pramipexole 0.2 mg
Study: 1350237
Drug: Pramipexole 0.3
Normalized name: pramipexole 0.375 mg oral tablet, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pramipexole 0.3 mg
Study: 3676230
Drug: Diet L
Normalized name: L-377202
DrugBank: L-377202 (DB19022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet L (50 g lactitol/d)
Study: 3676230
Drug: Diet S
Normalized name: Chewable Diet Supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet S (49 g saccharose/d)
Study: 20415914
Drug: Gumtone gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gumtone gel
Study: 16040409
Drug: Tazarotene 0.1%
Normalized name: TAZAROTENE 0.1% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tazarotene 0.1% gel plus petrolatum once daily
Study: 16040409
Drug: Calcipotriol 0.005%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriol 0.005% ointment twice daily
Study: 11791028
Drug: Irbesartan (AT1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan (AT1 antagonist)
Study: 10530535
Drug: Intravenous analgesia/sedation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous analgesia/sedation (IVAS)
Study: 10530535
Drug: Intraarticular lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraarticular lidocaine injection (IAL)
Study: 30485450
Drug: Placebo formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo formulation
Study: 15155349
Drug: 40 mL
Normalized name: hydrogen peroxide 40 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mL chloroprocaine 1%
Study: 15155349
Drug: 40 mL
Normalized name: hydrogen peroxide 40 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mL chloroprocaine 0.5%
Study: 8082071
Drug: Chemoembolization (5-fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemoembolization (5-fluorouracil 750 mg/m2 and recombinant alpha-2a-interferon 9-MU mixed into PVA contrast suspension)
Study: 2919760
Drug: Midazolam (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.3 mg/kg intravenously)
Study: 4025853
Drug: Thiopental (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopental (4 mg/kg)
Study: 31739784
Drug: Internal Brace
Normalized name: Brace Relief
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Internal Brace Ligament Augmentation (IBLA)
Study: 28072690
Drug: Insulin jet
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin jet injector (regular insulin and insulin aspart)
Study: 28072690
Drug: Insulin pen
Normalized name: INSULIN PEN (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin pen (regular insulin and insulin aspart)
Study: 25879228
Drug: Red yeast
Normalized name: red yeast
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red yeast rice and olive fruit extract (10.82 mg of monacolins and 9.32 mg of hydroxytyrosol per capsule)
Study: 20238221
Drug: Combined connective
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined connective tissue massage, Kabat's technique, kinesitherapy, and home exercise program for 9 weeks (twice a week, 1 hour per session)
Study: 19884713
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of in-office (CP37) and at-home (CP10) bleaching
Study: 17261397
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no statin treatment)
Study: 9695725
Drug: Entacapone (50,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Entacapone (50, 100, 200, or 400 mg)
Study: 28155060
Drug: Antibiotic-loaded DAC®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic-loaded DAC® hydrogel coating
Study: 25162362
Drug: PEG 4000
Normalized name: PEG 4000
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG 4000 at a dose of 0.7 g/kg (high-dose group)
Study: 25162362
Drug: PEG 4000
Normalized name: PEG 4000
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG 4000 at a dose of 0.3 g/kg (low-dose group)
Study: 12684359
Drug: Behavior Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavior Therapy (BT) and Sibutramine
Study: 12684359
Drug: Behavior Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavior Therapy (BT) and Placebo
Study: 12684359
Drug: Sibutramine (after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sibutramine (after initial treatment)
Study: 10194542
Drug: Irinotecan (CPT‐11)
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Irinotecan (CPT‐11) administered via 90 min i.v. infusion